
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7188418/publications.pdf Version: 2024-02-01



SHI-MING TU

#	Article	IF	CITATIONS
1	Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet, The, 2001, 357, 336-341.	13.7	384
2	ADULT PROSTATE SARCOMA: THE M. D. ANDERSON CANCER CENTER EXPERIENCE. Journal of Urology, 2001, 166, 521-525.	0.4	153
3	Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncology, The, 2002, 3, 508-513.	10.7	149
4	Prostate carcinoma with testicular or penile metastases. Cancer, 2002, 94, 2610-2617.	4.1	115
5	Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1–2 trial. Lancet Oncology, The, 2019, 20, 1432-1443.	10.7	115
6	Phase 2 study of pembrolizumab in patients with advanced rare cancers. , 2020, 8, e000347.		95
7	Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody. , 2016, 4, 36.		90
8	Platelet-Derived Growth Factor Receptor Inhibition and Chemotherapy for Castration-Resistant Prostate Cancer with Bone Metastases. Clinical Cancer Research, 2007, 13, 5816-5824.	7.0	84
9	Therapy Tolerance in Selected Patients With Androgen-Independent Prostate Cancer Following Strontium-89 Combined With Chemotherapy. Journal of Clinical Oncology, 2005, 23, 7904-7910.	1.6	63
10	Phase II trial of 5-fluorouracil, interferon-? and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer, 1997, 80, 2128-2132.	4.1	62
11	Ductal adenocarcinoma of the prostate. Cancer, 2009, 115, 2872-2880.	4.1	56
12	Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer. Journal of Clinical Oncology, 2009, 27, 3319-3324.	1.6	46
13	A Phase II trial of bryostatin-1 for patients with metastatic renal cell carcinoma. Cancer, 2000, 89, 615-618.	4.1	44
14	A Phase I/II study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases. Cancer, 2003, 97, 2988-2994.	4.1	39
15	Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer, 2016, 122, 1836-1843.	4.1	39
16	Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. Journal of Pathology, 2004, 203, 688-695.	4.5	36
17	Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Investigational New Drugs, 2021, 39, 1405-1410.	2.6	35
18	Prostate Cancer Stem Cells. Clinical Genitourinary Cancer, 2012, 10, 69-76.	1.9	33

#	Article	IF	CITATIONS
19	The central role of osteoblasts in the metastasis of prostate cancer. Cancer and Metastasis Reviews, 2007, 25, 601-609.	5.9	31
20	Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer. Urologic Oncology: Seminars and Original Investigations, 1996, 2, 191-197.	1.6	30
21	Association of Body Composition with Outcome of Docetaxel Chemotherapy in Metastatic Prostate Cancer: A Retrospective Review. PLoS ONE, 2015, 10, e0122047.	2.5	30
22	Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma. Cancer, 2003, 97, 561-567.	4.1	26
23	Current Trials Using Bone-Targeting Agents in Prostate Cancer. Cancer Journal (Sudbury, Mass), 2008, 14, 35-39.	2.0	25
24	Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. European Urology Oncology, 2021, 4, 651-658.	5.4	25
25	Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget, 2016, 7, 86280-86289.	1.8	25
26	Ductal Prostate Cancers Demonstrate Poor Outcomes with Conventional Therapies. European Urology, 2021, 79, 298-306.	1.9	24
27	Soluble ErbB3 Levels in Bone Marrow and Plasma of Men with Prostate Cancer. Clinical Cancer Research, 2008, 14, 3729-3736.	7.0	23
28	Origin of Subsequent Malignant Neoplasms in Patients with History of Testicular Germ Cell Tumor. Cancers, 2020, 12, 3755.	3.7	23
29	Introduction. Cancer Treatment and Research, 2010, 154, 1-5.	0.5	23
30	Optimizing the diagnosis and management of ductal prostate cancer. Nature Reviews Urology, 2021, 18, 337-358.	3.8	21
31	Pilot Trial of Bone-Targeted Therapy Combining Zoledronate With Fluvastatin or Atorvastatin for Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2011, 9, 81-88.	1.9	18
32	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. Oncologist, 2021, 26, 558-e1098.	3.7	18
33	Stem Cell Theory of Cancer: Origin of Tumor Heterogeneity and Plasticity. Cancers, 2021, 13, 4006.	3.7	18
34	Clinical Aspects of Bone Metastases in Prostate Cancer. Cancer Treatment and Research, 2004, 118, 23-46.	0.5	18
35	Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-Î ³ for metastatic renal cell carcinoma. Cancer, 2006, 107, 497-505.	4.1	14
36	Patterns of metastases of prostatic ductal adenocarcinoma. Cancer, 2020, 126, 3667-3673.	4.1	14

#	Article	IF	CITATIONS
37	Cancer: a "stem-cell―disease?. Cancer Cell International, 2013, 13, 40.	4.1	13
38	Randomized phase 2 study of boneâ€ŧargeted therapy containing strontiumâ€89 in advanced castrateâ€sensitive prostate cancer. Cancer, 2015, 121, 69-76.	4.1	13
39	Personalised cancer care: promises and challenges of targeted therapy. Journal of the Royal Society of Medicine, 2016, 109, 98-105.	2.0	13
40	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. Npj Precision Oncology, 2021, 5, 21.	5.4	12
41	Somatic-type Malignancies in Testicular Germ Cell Tumors. American Journal of Surgical Pathology, 2022, 46, 11-17.	3.7	12
42	The scientific method: pillar and pitfall of cancer research. Cancer Medicine, 2014, 3, 1035-1037.	2.8	11
43	Primary Malignant Thyroid Teratoma: An Institutional Experience. Thyroid, 2019, 29, 229-236.	4.5	11
44	A Phase II Study of Cabozantinib and Androgen Ablation in Patients with Hormone-NaÃ⁻ve Metastatic Prostate Cancer. Clinical Cancer Research, 2020, 26, 990-999.	7.0	11
45	Multimodality therapy: bone-targeted radioisotope therapy of prostate cancer. Clinical Advances in Hematology and Oncology, 2010, 8, 341-51.	0.3	11
46	Maintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case Series. Case Reports in Oncological Medicine, 2015, 2015, 1-5.	0.3	10
47	Safety of Same-day Pegfilgrastim Administration in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel With or Without Carboplatin. Clinical Genitourinary Cancer, 2017, 15, e429-e435.	1.9	10
48	Stem Cell Origin of Testicular Seminoma. Clinical Genitourinary Cancer, 2013, 11, 489-494.	1.9	9
49	Cabozantinib Reverses Renal Cell Carcinoma–mediated Osteoblast Inhibition in Three-dimensional Coculture <i>In Vitro</i> and Reduces Bone Osteolysis <i>In Vivo</i> . Molecular Cancer Therapeutics, 2020, 19, 1266-1278.	4.1	9
50	A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate Cancer. Clinical Genitourinary Cancer, 2021, 19, 22-31.e5.	1.9	8
51	Stem Cell Theory of Cancer: Rude Awakening or Bad Dream from Cancer Dormancy?. Cancers, 2022, 14, 655.	3.7	8
52	Very Late Recurrence in Germ Cell Tumor of the Testis: Lessons and Implications. Cancers, 2022, 14, 1127.	3.7	8
53	Stem Cell Theory of Cancer: Implications for Drug Resistance and Chemosensitivity in Cancer Care. Cancers, 2022, 14, 1548.	3.7	8
54	Managing seminomatous and nonseminomatous germ cell tumors. Current Opinion in Oncology, 2018, 30. 181-188.	2.4	7

#	Article	IF	CITATIONS
55	Comparison of Diagnostic Utility of Fluciclovine PET/CT Versus Pelvic Multiparametric MRI for Prostate Cancer in the Pelvis in the Setting of Rising PSA After Initial Treatment. Clinical Nuclear Medicine, 2020, 45, 349-355.	1.3	7
56	Systemic therapy for primary and extragonadal germ cell tumors: prognosis and nuances of treatment. Translational Andrology and Urology, 2020, 9, S56-S65.	1.4	7
57	Recurrent seminomas: Clinical features and biologic implications. Urologic Oncology: Seminars and Original Investigations, 2012, 30, 494-501.	1.6	6
58	Positive FDC-PET/CT Scans of a Residual Seminoma After Chemotherapy and Radiotherapy: Case Report and Review of the Literature. Clinical Genitourinary Cancer, 2014, 12, e147-e150.	1.9	6
59	Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemotherapy and Pharmacology, 2017, 80, 583-589.	2.3	6
60	A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancer. European Journal of Cancer, 2020, 127, 67-75.	2.8	6
61	Intraoperative and early postoperative complications in postchemotherapy retroperitoneal lymphadenectomy among patients with germ cell tumors using validated grading classifications. Cancer, 2020, 126, 4878-4885.	4.1	5
62	Testicular germ cell tumors type 2 have high RNA expression of LDHB, the gene for lactate dehydrogenase subunit B. Asian Journal of Andrology, 2021, 23, 357.	1.6	5
63	Stem Cell Theory of Cancer: Implications of a Viral Etiology in Certain Malignancies. Cancers, 2021, 13, 2738.	3.7	5
64	Curing Cancer: Lessons from a Prototype. Cancers, 2021, 13, 660.	3.7	4
65	Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naÃ ⁻ ve prostate cancer. European Journal of Cancer, 2021, 157, 259-267.	2.8	4
66	Variant prostate carcinoma and elevated serum CA-125. Canadian Journal of Urology, 2014, 21, 7442-8.	0.0	4
67	Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench. Cancers, 2022, 14, 3345.	3.7	4
68	Recent developments in the management of germ cell tumors. Current Opinion in Oncology, 2017, 29, 172-178.	2.4	3
69	Postacute Care in Cancer Rehabilitation. Physical Medicine and Rehabilitation Clinics of North America, 2017, 28, 19-34.	1.3	3
70	Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, α-interferon, cisplatin (FAP). Urologic Oncology: Seminars and Original Investigations, 2003, 21, 342-348.	1.6	2
71	Prolonged Remission of Upper Urinary Tract Urothelial Carcinoma With Prominent Choriocarcinomatous Differentiation: A Case Report. Clinical Genitourinary Cancer, 2017, 15, e73-e77.	1.9	2
72	ldentification of Glypican-3 (GPC3) Expression in a Lethal Subgroup of Refractory Cisplatin-Resistant Testicular Germ-Cell Tumors. Clinical Genitourinary Cancer, 2018, 16, 325-327.	1.9	2

#	Article	IF	CITATIONS
73	A prospective, multicenter, randomized phase II trial of best systemic therapy (BST) or BST plus definitive treatment (Surgery or Radiation) of the primary tumor in metastatic prostate cancer Journal of Clinical Oncology, 2015, 33, TPS5075-TPS5075.	1.6	2
74	Cancer Stem Cells. Cancer Treatment and Research, 2010, , 67-81.	0.5	2
75	Diagnostic performance of F-fluciclovine PET/CT in prostate cancer patients with rising PSA level â‰ø.5 ng/ml after multiple treatment failures. American Journal of Nuclear Medicine and Molecular Imaging, 2021, 11, 87-98.	1.0	2
76	Application of a Successful Germ Cell Tumor Paradigm to the Challenges of Common Adult Solid Cancers. Journal of Cell Science & Therapy, 2021, 12, .	0.3	2
77	Stem-Cell Theory of Cancer: Implications for Antiaging and Anticancer Strategies. Cancers, 2022, 14, 1338.	3.7	2
78	Stem Cell Theory of Cancer: Origin of Metastasis and Sub-clonality. Seminars in Diagnostic Pathology, 2023, 40, 63-68.	1.5	2
79	Radiopharmaceuticals: Present and Future. The Journal of Supportive Oncology, 2011, 9, 206-207.	2.3	1
80	The Cancer Genome: Paradigm or Paradox?. Cancers, 2021, 13, 674.	3.7	1
81	Very late recurrence in germ cell tumor of the testis: Lessons and implications Journal of Clinical Oncology, 2021, 39, 5030-5030.	1.6	1
82	Prolonged Remission of Fulminant Castrate-Resistant Prostate Cancer: A Case Report. Clinical Genitourinary Cancer, 2011, 9, 133-136.	1.9	0
83	Rapidly enlarging abdominal mass in a patient with recurrent germ cell tumor. Clinical Case Reports (discontinued), 2019, 7, 2285-2286.	0.5	0
84	Cancer Niche. Cancer Treatment and Research, 2010, , 83-91.	0.5	0
85	Curing Cancer. Cancer Treatment and Research, 2010, , 215-225.	0.5	0
86	Drug Resistance. Cancer Treatment and Research, 2010, , 161-175.	0.5	0
87	Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT) Journal of Clinical Oncology, 2014, 32, 4517-4517.	1.6	0
88	Editorial Comment. Journal of Urology, 2020, 203, 1154-1154.	0.4	0